{
    "abstract": "This Phase I/II, open, long-term follow-up study was conducted in antiretroviral therapy (ART)-na\u00efve (N = 212) and ART-treated (N = 19) human immunodeficiency virus 1 (HIV-1)-infected adults, who received an HIV-1 investigational vaccine (F4/AS01B) or placebo in two previous studies (NCT00814762 and NCT01218113). After a minimum of two years and a maximum of four years of follow-up post-vaccination per patient, no significant differences were observed between F4/AS01B and placebo groups in terms of viral load, CD4+ T-cell count and incidence of specific clinical events. Vaccine-induced polyfunctional CD4+ T-cells persisted up to study end and no relevant vaccine-related safety events were reported in F4/AS01B groups. This study has been registered at ClinicalTrials.gov (NCT01092611).",
    "author_highlights": [
        {
            "endOffset": 7718,
            "sentence": "F4/AS01B is a human immunodeficiency virus 1 (HIV-1) investigational vaccine.",
            "startOffset": 7641
        },
        {
            "endOffset": 7801,
            "sentence": "After \u22652 years of follow-up, F4/AS01B was well-tolerated in HIV-1-infected adults.",
            "startOffset": 7719
        },
        {
            "endOffset": 7885,
            "sentence": "A previous trial showed no clinical benefit of F4/AS01B in HIV-1-infected patients.",
            "startOffset": 7802
        },
        {
            "endOffset": 7968,
            "sentence": "The conclusion of the previous trial was unchanged after this long-term follow-up.",
            "startOffset": 7886
        },
        {
            "endOffset": 8053,
            "sentence": "Polyfunctional CD4+ T-cells persisted for \u22652 years after administration of F4/AS01B.",
            "startOffset": 7969
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Van Braeckel"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Bourguignon"
                },
                {
                    "first": "Marguerite",
                    "initial": "M.",
                    "last": "Koutsoukos"
                },
                {
                    "first": "Fr\u00e9d\u00e9ric",
                    "initial": "F.",
                    "last": "Clement"
                },
                {
                    "first": "Michel",
                    "initial": "M.",
                    "last": "Janssens"
                },
                {
                    "first": "Isabelle",
                    "initial": "I.",
                    "last": "Carletti"
                },
                {
                    "first": "Alix",
                    "initial": "A.",
                    "last": "Collard"
                },
                {
                    "first": "Marie Ange",
                    "initial": "M.A.",
                    "last": "Demoiti\u00e9"
                },
                {
                    "first": "Gerald",
                    "initial": "G.",
                    "last": "Voss"
                },
                {
                    "first": "Geert",
                    "initial": "G.",
                    "last": "Leroux-Roels"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "McNally"
                }
            ],
            "doi": "10.1093/cid/ciq160",
            "firstpage": "522",
            "issn": "10584838",
            "lastpage": "531",
            "pmid": "21208909",
            "pub_year": 2011,
            "title": "An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers",
            "volume": "52"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Isabel",
                    "initial": "I.",
                    "last": "Leroux-Roels"
                },
                {
                    "first": "Marguerite",
                    "initial": "M.",
                    "last": "Koutsoukos"
                },
                {
                    "first": "Fr\u00e9d\u00e9ric",
                    "initial": "F.",
                    "last": "Clement"
                },
                {
                    "first": "Sophia",
                    "initial": "S.",
                    "last": "Steyaert"
                },
                {
                    "first": "Michel",
                    "initial": "M.",
                    "last": "Janssens"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Bourguignon"
                },
                {
                    "first": "Kristen",
                    "initial": "K.",
                    "last": "Cohen"
                },
                {
                    "first": "Marcus",
                    "initial": "M.",
                    "last": "Altfeld"
                },
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Vandepapeli\u00e8re"
                },
                {
                    "first": "Louise",
                    "initial": "L.",
                    "last": "Pedneault"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "McNally"
                },
                {
                    "first": "Geert",
                    "initial": "G.",
                    "last": "Leroux-Roels"
                },
                {
                    "first": "Gerald",
                    "initial": "G.",
                    "last": "Voss"
                }
            ],
            "doi": "10.1016/j.vaccine.2010.08.035",
            "firstpage": "7016",
            "issn": "0264410X",
            "lastpage": "7024",
            "pmid": "20728522",
            "pub_year": 2010,
            "title": "Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems",
            "volume": "28"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Warren",
                    "initial": "W.",
                    "last": "Dinges"
                },
                {
                    "first": "Pierre Marie",
                    "initial": "P.M.",
                    "last": "Girard"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Podzamczer"
                },
                {
                    "first": "Norbert H.",
                    "initial": "N.H.",
                    "last": "Brockmeyer"
                },
                {
                    "first": "Felipe",
                    "initial": "F.",
                    "last": "Garc\u00eda"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Harrer"
                },
                {
                    "first": "Jean Daniel",
                    "initial": "J.D.",
                    "last": "Lelievre"
                },
                {
                    "first": "Ian",
                    "initial": "I.",
                    "last": "Frank"
                },
                {
                    "first": "Nathalie Colin",
                    "initial": "N.C.",
                    "last": "De Verdi\u00e8re"
                },
                {
                    "first": "Guy Patrick",
                    "initial": "G.P.",
                    "last": "Yeni"
                },
                {
                    "first": "Enrique Ortega",
                    "initial": "E.O.",
                    "last": "Gonzalez"
                },
                {
                    "first": "Rafael",
                    "initial": "R.",
                    "last": "Rubio"
                },
                {
                    "first": "Bonaventura Clotet",
                    "initial": "B.C.",
                    "last": "Sala"
                },
                {
                    "first": "Edwin",
                    "initial": "E.",
                    "last": "DeJesus"
                },
                {
                    "first": "Maria Jesus",
                    "initial": "M.J.",
                    "last": "P\u00e9rez-Elias"
                },
                {
                    "first": "Odile",
                    "initial": "O.",
                    "last": "Launay"
                },
                {
                    "first": "Gilles",
                    "initial": "G.",
                    "last": "Pialoux"
                },
                {
                    "first": "Jihad",
                    "initial": "J.",
                    "last": "Slim"
                },
                {
                    "first": "Laurence",
                    "initial": "L.",
                    "last": "Weiss"
                },
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Bouchaud"
                },
                {
                    "first": "Franco",
                    "initial": "F.",
                    "last": "Felizarta"
                },
                {
                    "first": "Anja",
                    "initial": "A.",
                    "last": "Meurer"
                },
                {
                    "first": "Fran\u00e7ois",
                    "initial": "F.",
                    "last": "Raffi"
                },
                {
                    "first": "Stefan",
                    "initial": "S.",
                    "last": "Esser"
                },
                {
                    "first": "Christine",
                    "initial": "C.",
                    "last": "Katlama"
                },
                {
                    "first": "Susan L.",
                    "initial": "S.L.",
                    "last": "Koletar"
                },
                {
                    "first": "Karam",
                    "initial": "K.",
                    "last": "Mounzer"
                },
                {
                    "first": "Susan",
                    "initial": "S.",
                    "last": "Swindells"
                },
                {
                    "first": "John D.",
                    "initial": "J.D.",
                    "last": "Baxter"
                },
                {
                    "first": "Stefan",
                    "initial": "S.",
                    "last": "Schneider"
                },
                {
                    "first": "Julie",
                    "initial": "J.",
                    "last": "Chas"
                },
                {
                    "first": "Jean Michel",
                    "initial": "J.M.",
                    "last": "Molina"
                },
                {
                    "first": "Marguerite",
                    "initial": "M.",
                    "last": "Koutsoukos"
                },
                {
                    "first": "Alix",
                    "initial": "A.",
                    "last": "Collard"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Bourguignon"
                },
                {
                    "first": "Fran\u00e7ois",
                    "initial": "F.",
                    "last": "Roman"
                }
            ],
            "doi": "10.1097/MD.0000000000002673",
            "issn": "00257974",
            "pmid": "26871794",
            "pub_year": 2016,
            "title": "The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, but Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial",
            "volume": "95"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Harrer"
                },
                {
                    "first": "Andreas",
                    "initial": "A.",
                    "last": "Plettenberg"
                },
                {
                    "first": "Keikawus",
                    "initial": "K.",
                    "last": "Arast\u00e9h"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Van Lunzen"
                },
                {
                    "first": "Gerd",
                    "initial": "G.",
                    "last": "F\u00e4tkenheuer"
                },
                {
                    "first": "Hans",
                    "initial": "H.",
                    "last": "Jaeger"
                },
                {
                    "first": "Michel",
                    "initial": "M.",
                    "last": "Janssens"
                },
                {
                    "first": "Wivine",
                    "initial": "W.",
                    "last": "Burny"
                },
                {
                    "first": "Alix",
                    "initial": "A.",
                    "last": "Collard"
                },
                {
                    "first": "Fran\u00e7ois",
                    "initial": "F.",
                    "last": "Roman"
                },
                {
                    "first": "Alfred",
                    "initial": "A.",
                    "last": "Loeliger"
                },
                {
                    "first": "Marguerite",
                    "initial": "M.",
                    "last": "Koutsoukos"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Bourguignon"
                },
                {
                    "first": "Ludo",
                    "initial": "L.",
                    "last": "Lavreys"
                },
                {
                    "first": "Gerald",
                    "initial": "G.",
                    "last": "Voss"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.10.030",
            "firstpage": "2657",
            "issn": "0264410X",
            "lastpage": "2665",
            "pmid": "24144472",
            "pub_year": 2014,
            "title": "Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: A randomised placebo-controlled study",
            "volume": "32"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Paul A.",
                    "initial": "P.A.",
                    "last": "Goepfert"
                },
                {
                    "first": "Georgia D.",
                    "initial": "G.D.",
                    "last": "Tomaras"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Horton"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Montefiori"
                },
                {
                    "first": "Guido",
                    "initial": "G.",
                    "last": "Ferrari"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Deers"
                },
                {
                    "first": "Gerald",
                    "initial": "G.",
                    "last": "Voss"
                },
                {
                    "first": "Marguerite",
                    "initial": "M.",
                    "last": "Koutsoukos"
                },
                {
                    "first": "Louise",
                    "initial": "L.",
                    "last": "Pedneault"
                },
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Vandepapeliere"
                },
                {
                    "first": "M. Juliana",
                    "initial": "M.J.",
                    "last": "McElrath"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Spearman"
                },
                {
                    "first": "Jonathan D.",
                    "initial": "J.D.",
                    "last": "Fuchs"
                },
                {
                    "first": "Beryl A.",
                    "initial": "B.A.",
                    "last": "Koblin"
                },
                {
                    "first": "William A.",
                    "initial": "W.A.",
                    "last": "Blattner"
                },
                {
                    "first": "Sharon",
                    "initial": "S.",
                    "last": "Frey"
                },
                {
                    "first": "Lindsey R.",
                    "initial": "L.R.",
                    "last": "Baden"
                },
                {
                    "first": "Clayton",
                    "initial": "C.",
                    "last": "Harro"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Evans"
                }
            ],
            "doi": "10.1016/j.vaccine.2006.07.050",
            "firstpage": "510",
            "issn": "0264410X",
            "lastpage": "518",
            "pmid": "17049679",
            "pub_year": 2007,
            "title": "Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers",
            "volume": "25"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Juliet",
                    "initial": "J.",
                    "last": "Mpendo"
                },
                {
                    "first": "Gaudensia",
                    "initial": "G.",
                    "last": "Mutua"
                },
                {
                    "first": "Julien",
                    "initial": "J.",
                    "last": "Nyombayire"
                },
                {
                    "first": "Rosine",
                    "initial": "R.",
                    "last": "Ingabire"
                },
                {
                    "first": "Annet",
                    "initial": "A.",
                    "last": "Nanvubya"
                },
                {
                    "first": "Omu",
                    "initial": "O.",
                    "last": "Anzala"
                },
                {
                    "first": "Etienne",
                    "initial": "E.",
                    "last": "Karita"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Hayes"
                },
                {
                    "first": "Jakub",
                    "initial": "J.",
                    "last": "Kopycinski"
                },
                {
                    "first": "Len",
                    "initial": "L.",
                    "last": "Dally"
                },
                {
                    "first": "Drew",
                    "initial": "D.",
                    "last": "Hannaman"
                },
                {
                    "first": "Michael A.",
                    "initial": "M.A.",
                    "last": "Egan"
                },
                {
                    "first": "John H.",
                    "initial": "J.H.",
                    "last": "Eldridge"
                },
                {
                    "first": "Kristen",
                    "initial": "K.",
                    "last": "Syvertsen"
                },
                {
                    "first": "Jennifer",
                    "initial": "J.",
                    "last": "Lehrman"
                },
                {
                    "first": "Beth",
                    "initial": "B.",
                    "last": "Rasmussen"
                },
                {
                    "first": "Jill",
                    "initial": "J.",
                    "last": "Gilmour"
                },
                {
                    "first": "Josephine H.",
                    "initial": "J.H.",
                    "last": "Cox"
                },
                {
                    "first": "Patricia E.",
                    "initial": "P.E.",
                    "last": "Fast"
                },
                {
                    "first": "Claudia",
                    "initial": "C.",
                    "last": "Schmidt"
                }
            ],
            "doi": "10.1371/journal.pone.0134287",
            "issn": "19326203",
            "pmid": "26252526",
            "pub_year": 2015,
            "title": "A phase I double blind, placebo-controlled, randomized study of the safety and immunogenicity of electroporated HIV DNA with or without interleukin 12 in prime-boost combinations with an Ad35 HIV vaccine in healthy HIV-seronegative african adults",
            "volume": "10"
        }
    },
    "body_text": [
        {
            "endOffset": 9718,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 9652,
                    "startOffset": 9649
                }
            },
            "secId": "s0005",
            "sentence": "Based on previous findings [2], the F4 protein has been combined with the AS01B adjuvant system.",
            "startOffset": 9622,
            "title": "Introduction"
        },
        {
            "endOffset": 15009,
            "parents": [],
            "secId": "s0015",
            "sentence": "Among 212 ART-na\u00efve patients eligible for this extension study, 171 patients had data available at Year 1, corresponding to their last visit in the primary study (approximately 1 year after first vaccination).",
            "startOffset": 14800,
            "title": "Results and discussion"
        },
        {
            "endOffset": 14237,
            "parents": [],
            "secId": "s0010",
            "sentence": "Results were summarised using descriptive statistics for continuous variables and percentages with 95% confidence intervals (CIs) for categorical variables.",
            "startOffset": 14081,
            "title": "Methods"
        },
        {
            "endOffset": 19354,
            "parents": [],
            "secId": "s0020",
            "sentence": "Although evidence is still lacking on cure strategies, the T-cell responses induced by F4/AS01B could be of value for eliminating latent viral reservoirs in combination with ART and latency reversing agents.",
            "startOffset": 19147,
            "title": "Conclusions"
        },
        {
            "endOffset": 13003,
            "parents": [],
            "secId": "s0010",
            "sentence": "For the evaluation of the persistence of immune responses, extra blood volume was taken in conjunction with planned blood sampling from participants who consented to this procedure.",
            "startOffset": 12822,
            "title": "Methods"
        },
        {
            "endOffset": 17195,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 17194,
                    "startOffset": 17189
                },
                "b0010": {
                    "endOffset": 17194,
                    "startOffset": 17189
                },
                "b0015": {
                    "endOffset": 17194,
                    "startOffset": 17189
                },
                "b0020": {
                    "endOffset": 17194,
                    "startOffset": 17189
                },
                "b0025": {
                    "endOffset": 17194,
                    "startOffset": 17189
                },
                "b0030": {
                    "endOffset": 17194,
                    "startOffset": 17189
                }
            },
            "secId": "s0015",
            "sentence": "No additional relevant safety outcomes related to F4/AS01B were reported, confirming the previously observed acceptable safety profile [1\u20136].",
            "startOffset": 17054,
            "title": "Results and discussion"
        },
        {
            "endOffset": 17499,
            "parents": [],
            "secId": "s0015",
            "sentence": "No vaccine-related pIMDs or deaths were reported.",
            "startOffset": 17450,
            "title": "Results and discussion"
        },
        {
            "endOffset": 15378,
            "parents": [],
            "secId": "s0015",
            "sentence": "Among 19 eligible ART-treated patients (9 in F4/AS01B and 10 in placebo group), all patients had data available at Years 1 and 2, 17 at Year 3, and 14 at Year 4.",
            "startOffset": 15217,
            "title": "Results and discussion"
        },
        {
            "endOffset": 17054,
            "parents": [],
            "secId": "s0015",
            "sentence": "Among ART-treated participants, non-AIDS defining malignancies were reported in two participants from F4/AS01B group and no participants experienced disease progression.",
            "startOffset": 16885,
            "title": "Results and discussion"
        },
        {
            "endOffset": 18718,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 18717,
                    "startOffset": 18712
                },
                "b0020": {
                    "endOffset": 18717,
                    "startOffset": 18712
                }
            },
            "secId": "s0015",
            "sentence": "This observation is consistent with the primary studies and may be explained by the higher pre-vaccination titres observed in ART-na\u00efve patients [3,4].",
            "startOffset": 18567,
            "title": "Results and discussion"
        },
        {
            "endOffset": 17654,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 17653,
                    "startOffset": 17648
                },
                "b0020": {
                    "endOffset": 17653,
                    "startOffset": 17648
                }
            },
            "secId": "s0015",
            "sentence": "This extension study showed that CD4+ T-cells induced by two or three doses of F4/AS01B persisted up to study end in magnitude and polyfunctionality [3,4].",
            "startOffset": 17499,
            "title": "Results and discussion"
        },
        {
            "endOffset": 15090,
            "parents": [],
            "secId": "s0015",
            "sentence": "Of these, 114 and 57 patients were in F4/AS01B and placebo groups, respectively.",
            "startOffset": 15010,
            "title": "Results and discussion"
        },
        {
            "endOffset": 14081,
            "parents": [],
            "secId": "s0010",
            "sentence": "For VL, CD4+ T-cell count, and immunogenicity analyses, data collected after ART-initiation were censored.",
            "startOffset": 13975,
            "title": "Methods"
        },
        {
            "endOffset": 16775,
            "parents": [],
            "secId": "s0015",
            "sentence": "Specific clinical events were reported in one ART-na\u00efve participant from F4/AS01B group (herpes zoster disease) and two ART-na\u00efve participants from placebo group (both non-AIDS defining malignancies).",
            "startOffset": 16575,
            "title": "Results and discussion"
        },
        {
            "endOffset": 17833,
            "parents": [],
            "secId": "s0015",
            "sentence": "In the ATP immunogenicity cohort, persistence of CD40L+CD4+ T-cells expressing at least IL-2 was observed in ART-treated and ART-na\u00efve participants from F4/AS01B groups (Fig. 1).",
            "startOffset": 17655,
            "title": "Results and discussion"
        },
        {
            "endOffset": 12189,
            "parents": [],
            "secId": "s0010",
            "sentence": "To minimise the impact on patient\u2019s follow-up, information was collected as part of routine medical care at approximately one-year intervals.",
            "startOffset": 12048,
            "title": "Methods"
        },
        {
            "endOffset": 14525,
            "parents": [],
            "secId": "s0010",
            "sentence": "F4-specific CD4+ T-cell responses were estimated from the sum of specific CD4+ T-cell frequencies in response to each individual antigen (p17, p24, RT, or Nef) and were characterised based on frequencies of CD40L+CD4+ T-cells expressing at least IL-2 and cytokine co-expression profiles.",
            "startOffset": 14238,
            "title": "Methods"
        },
        {
            "endOffset": 11520,
            "parents": [],
            "secId": "s0010",
            "sentence": "In this extension study, participants were grouped according to treatment (F4/AS01B or placebo) and status (ART-treated or ART-na\u00efve) at the start of the primary study.",
            "startOffset": 11352,
            "title": "Methods"
        },
        {
            "endOffset": 12821,
            "parents": [],
            "secId": "s0010",
            "sentence": "The following safety variables were recorded: pre-defined clinical events (symptomatic conditions occurring in HIV-1-infected patients, which are attributed to HIV-1 infections, indicate defects in cell-mediated immunity, or are considered to have a clinical course or management complicated by HIV-1 infection; and non-AIDS defining malignancies, including cardiovascular diseases, end-stage renal diseases, chronic liver diseases, metabolic events and deaths); adverse events (AEs) considered vaccine-related by the investigators; potential immune-mediated diseases (pIMDs); and serious AEs (SAEs) related to study participation.",
            "startOffset": 12190,
            "title": "Methods"
        },
        {
            "endOffset": 11127,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 11126,
                    "startOffset": 11123
                }
            },
            "secId": "s0010",
            "sentence": "The first was a Phase I study (NCT00814762), where ART-treated and ART-na\u00efve HIV-1-infected participants were randomised to receive two doses of F4/AS01B or placebo [4].",
            "startOffset": 10958,
            "title": "Methods"
        },
        {
            "endOffset": 18566,
            "parents": [],
            "secId": "s0015",
            "sentence": "While F4/AS01B had no impact on antibody levels in ART-na\u00efve participants, antibody GMCs tended to be higher in F4/AS01B than in placebo group at Year 2 in ART-treated participants (anti-Nef: 634.7 mEU/mL [95% CI, 303.8\u20131326.1] versus 290.9 mEU/mL [197.6\u2013428.2]; anti-p17: 895.8 mEU/mL [241.4\u20133324.5] versus 188.9 mEU/mL [79.3\u2013450.2]; anti-p24: 3667.4 mEU/mL [608.3\u201322109.4] versus 1287.8 mEU/mL [263.0\u20136307.4]; and anti-RT: 2883.7 mEU/mL [844.1\u20139851.4] versus 620.0 mEU/mL [145.3\u20132646.3]).",
            "startOffset": 18076,
            "title": "Results and discussion"
        },
        {
            "endOffset": 12048,
            "parents": [],
            "secId": "s0010",
            "sentence": "Secondary objectives included the evaluation of HIV-1-specific cellular and humoral immune responses to F4/AS01B in HIV-1-infected adults.",
            "startOffset": 11910,
            "title": "Methods"
        },
        {
            "endOffset": 13198,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 13197,
                    "startOffset": 13194
                }
            },
            "secId": "s0010",
            "sentence": "F4-specific CD4+ and CD8+ T-cell responses were measured by flow cytometry using intracellular cytokine staining, and antibody levels by standard in-house enzyme-linked immunosorbent assays [1].",
            "startOffset": 13004,
            "title": "Methods"
        },
        {
            "endOffset": 11909,
            "parents": [],
            "secId": "s0010",
            "sentence": "Primary objectives were to assess the long-term health status, CD4+ T-cell count, VL kinetics, time to (re)initiation of ART, incidence of specific clinical events, and safety in HIV-1-infected patients who received F4/AS01B.",
            "startOffset": 11684,
            "title": "Methods"
        },
        {
            "endOffset": 15785,
            "parents": [],
            "secId": "s0015",
            "sentence": "This extension study confirmed the lack of clinical benefit of F4/AS01B in HIV-1-infected participants, as no significant differences were observed between F4/AS01B and placebo groups in terms of VL, CD4+ T-cell count, and incidence of specific clinical events.",
            "startOffset": 15524,
            "title": "Results and discussion"
        },
        {
            "endOffset": 18075,
            "parents": [],
            "secId": "s0015",
            "sentence": "Although vaccine-induced CD4+ T-cells exhibited a polyfunctional phenotype throughout the study, proportions of F4-specific CD40L+CD4+ T-cells expressing two or three cytokines tended to decrease over time in ART-na\u00efve participants (Fig. 2).",
            "startOffset": 17834,
            "title": "Results and discussion"
        },
        {
            "endOffset": 19146,
            "parents": [],
            "secId": "s0020",
            "sentence": "This extension study confirmed that F4/AS01B has a clinically acceptable safety profile and induces CD4+ T-cells that persisted both in magnitude and polyfunctionality for at least two years in HIV-1-infected adults.",
            "startOffset": 18930,
            "title": "Conclusions"
        },
        {
            "endOffset": 13406,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 13405,
                    "startOffset": 13400
                },
                "b0020": {
                    "endOffset": 13405,
                    "startOffset": 13400
                }
            },
            "secId": "s0010",
            "sentence": "Study protocols were approved by local ethics committees and regulatory authorities, and the study was conducted in accordance with the Good Clinical Practice guidelines and the Declaration of Helsinki [3,4].",
            "startOffset": 13198,
            "title": "Methods"
        },
        {
            "endOffset": 16412,
            "parents": [],
            "secId": "s0015",
            "sentence": "The main reason for first ART-initiation was CD4+ T-cells decline (43.2% [95% CI, 27.1\u201360.5%] and 46.4% [27.5\u201366.1%] in F4/AS01B and placebo groups).",
            "startOffset": 16263,
            "title": "Results and discussion"
        },
        {
            "endOffset": 10486,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 10485,
                    "startOffset": 10480
                },
                "b0020": {
                    "endOffset": 10485,
                    "startOffset": 10480
                }
            },
            "secId": "s0005",
            "sentence": "This study is an extension of two trials (a phase I and a phase II), which was initially planned to monitor the long-term health status of participants and evaluate the benefits and risks associated with F4/AS01B vaccination in ART-na\u00efve HIV-1-infected adults [3,4].",
            "startOffset": 10220,
            "title": "Introduction"
        },
        {
            "endOffset": 14690,
            "parents": [],
            "secId": "s0010",
            "sentence": "Anti-p17, -p24, -RT, and -Nef antibody geometric mean concentrations (GMCs) were calculated by taking the anti-log10 of the mean of the log10 value transformations.",
            "startOffset": 14526,
            "title": "Methods"
        },
        {
            "endOffset": 10220,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 10219,
                    "startOffset": 10216
                }
            },
            "secId": "s0005",
            "sentence": "However, a previous proof-of-concept study showed that two or three doses of F4/AS01B did not reduce HIV-1 viral load (VL), impact CD4+ T-cells count, delay ART-initiation, or prevent HIV-1-related clinical events in ART-na\u00efve HIV-1-infected patients [3].",
            "startOffset": 9965,
            "title": "Introduction"
        },
        {
            "endOffset": 15524,
            "parents": [],
            "secId": "s0015",
            "sentence": "Demographic characteristics of study participants were consistent between F4/AS01B and placebo groups in both ART-treated and ART-na\u00efve patients.",
            "startOffset": 15379,
            "title": "Results and discussion"
        },
        {
            "endOffset": 13634,
            "parents": [],
            "secId": "s0010",
            "sentence": "This study has been registered at http://www.clinicaltrials.gov NCT01092611.",
            "startOffset": 13558,
            "title": "Methods"
        },
        {
            "endOffset": 14777,
            "parents": [],
            "secId": "s0010",
            "sentence": "Analyses were performed using SAS software version 9.2 (SAS Institute Inc., Cary, NC).",
            "startOffset": 14691,
            "title": "Methods"
        },
        {
            "endOffset": 9964,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 9876,
                    "startOffset": 9873
                },
                "b0015": {
                    "endOffset": 9963,
                    "startOffset": 9958
                },
                "b0020": {
                    "endOffset": 9963,
                    "startOffset": 9958
                }
            },
            "secId": "s0005",
            "sentence": "The F4/AS01B vaccine has a clinically acceptable safety profile and induces polyfunctional F4-specific CD4+ T-cell responses in HIV-1-seronegative adults [1], and in antiretroviral therapy (ART)-na\u00efve and ART-treated HIV-1-infected adults [3,4].",
            "startOffset": 9719,
            "title": "Introduction"
        },
        {
            "endOffset": 11684,
            "parents": [],
            "secId": "s0010",
            "sentence": "Study participants were HIV-1-infected adults, who received a complete vaccination course in one of the previous studies and had provided written informed consent.",
            "startOffset": 11521,
            "title": "Methods"
        },
        {
            "endOffset": 13803,
            "parents": [],
            "secId": "s0010",
            "sentence": "Safety analyses, CD4+ T-cell counts, and HIV-1 VL measurements were performed on the total vaccinated cohort (TVC), including all participants from both primary studies.",
            "startOffset": 13634,
            "title": "Methods"
        },
        {
            "endOffset": 9621,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 9620,
                    "startOffset": 9617
                }
            },
            "secId": "s0005",
            "sentence": "These antigens have been selected according to their critical role in HIV-1 pathogenesis and the high number of CD4+ T-cell epitopes present [1].",
            "startOffset": 9476,
            "title": "Introduction"
        },
        {
            "endOffset": 18918,
            "parents": [],
            "secId": "s0015",
            "sentence": "This observational study with no confirmatory objective had several limitations, such as the open design, the small number of participants, especially in ART-treated groups, and the early termination.",
            "startOffset": 18718,
            "title": "Results and discussion"
        },
        {
            "endOffset": 16103,
            "parents": [],
            "secId": "s0015",
            "sentence": "In ART-na\u00efve participants from the TVC who were not censored at Year 2, mean (standard deviation [SD]) HIV-1 VL values were 4.3 (0.7) versus 4.4 (0.5) log10 copies/mL, and mean (SD) absolute number of CD4+ T-cells were 599.5 (201.1) versus 559.0 (177.1) in F4/AS01B (N = 86) and placebo (N = 50) groups, respectively.",
            "startOffset": 15786,
            "title": "Results and discussion"
        },
        {
            "endOffset": 10957,
            "parents": [],
            "secId": "s0010",
            "sentence": "This Phase I/II, open, prospective, observational study (NCT01092611) conducted in France, Germany, Spain and the United States between March 22, 2010 and August 12, 2015 was an extension of two randomised, observer-blind, placebo-controlled clinical trials.",
            "startOffset": 10699,
            "title": "Methods"
        },
        {
            "endOffset": 16262,
            "parents": [],
            "secId": "s0015",
            "sentence": "The percentage of participants with ART-initiation was 33.6% (95% CI, 25.7\u201342.1%) in the F4/AS01B group compared with 46.7% (35.1\u201358.6%) in the placebo group.",
            "startOffset": 16104,
            "title": "Results and discussion"
        },
        {
            "endOffset": 15216,
            "parents": [],
            "secId": "s0015",
            "sentence": "Due to the early termination of the study, data were available for 157, 42 and 12 patients at Years 2, 3 and 4, respectively.",
            "startOffset": 15091,
            "title": "Results and discussion"
        },
        {
            "endOffset": 16884,
            "parents": [],
            "secId": "s0015",
            "sentence": "HIV-1 disease progression was experienced by four participants (three in F4/AS01B and one in placebo group).",
            "startOffset": 16776,
            "title": "Results and discussion"
        },
        {
            "endOffset": 17449,
            "parents": [],
            "secId": "s0015",
            "sentence": "One SAE (lymphoma), initially deemed to be related to vaccination, was reported in an ART-na\u00efve participant from placebo group, and two non-vaccine related SAEs (lung adenocarcinoma and anal cancer) in ART-treated participants from F4/AS01B group (TVC).",
            "startOffset": 17196,
            "title": "Results and discussion"
        },
        {
            "endOffset": 11351,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 11350,
                    "startOffset": 11347
                }
            },
            "secId": "s0010",
            "sentence": "The second was a Phase IIb study (NCT01218113), where ART-na\u00efve HIV-1-infected adults were randomised (1:1:1) to receive three doses of F4/AS01B, two doses of F4/AS01B and one dose of placebo, or three doses of placebo [3].",
            "startOffset": 11128,
            "title": "Methods"
        },
        {
            "endOffset": 9475,
            "parents": [],
            "secId": "s0005",
            "sentence": "The F4/AS01B vaccine is a human immunodeficiency virus 1 (HIV-1) investigational vaccine, which contains a recombinant fusion protein (F4) encoding 4 HIV-1 clade B antigens: p24, reverse transcriptase, regulatory protein Nef and p17.",
            "startOffset": 9242,
            "title": "Introduction"
        },
        {
            "endOffset": 13974,
            "parents": [],
            "secId": "s0010",
            "sentence": "Immunogenicity analyses were performed on the according-to-protocol (ATP) immunogenicity cohort, including participants with at least one immunogenicity result available.",
            "startOffset": 13804,
            "title": "Methods"
        },
        {
            "endOffset": 13557,
            "parents": [],
            "secId": "s0010",
            "sentence": "Informed consent was obtained from participants in the primary study and prior to performance of any study-specific procedure in this extension study.",
            "startOffset": 13407,
            "title": "Methods"
        },
        {
            "endOffset": 10691,
            "parents": [],
            "secId": "s0005",
            "sentence": "Since the proof-of-concept study failed to demonstrate clinical benefits following vaccination, the study was prematurely terminated after a minimum of two years of follow-up post-vaccination per patient.",
            "startOffset": 10487,
            "title": "Introduction"
        },
        {
            "endOffset": 16574,
            "parents": [],
            "secId": "s0015",
            "sentence": "Percentages of ART-treated participants with ART-modification were 44.4% (95% CI, 13.7\u201378.8%) and 30.0% (6.7\u201365.2%) in F4/AS01B and placebo groups, respectively.",
            "startOffset": 16413,
            "title": "Results and discussion"
        }
    ],
    "docId": "S0264410X18303888",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "Thomas.Harrer@uk-erlangen.de",
                "first": "Thomas",
                "initial": "T.",
                "last": "Harrer"
            },
            {
                "email": "wdinges@seattleidc.com",
                "first": "Warren",
                "initial": "W.",
                "last": "Dinges"
            },
            {
                "email": "FRANCOIS.P.ROMAN@GSK.COM",
                "first": "Fran\u00e7ois",
                "initial": "F.",
                "last": "Roman"
            },
            {
                "email": null,
                "first": null,
                "initial": null,
                "last": null
            }
        ],
        "doi": "10.1016/j.vaccine.2018.03.043",
        "firstpage": "2683",
        "issn": "0264410X",
        "keywords": [
            "Efficacy",
            "HIV type 1 vaccine",
            "Immunogenicity",
            "Persistence",
            "Recombinant fusion protein",
            "Safety"
        ],
        "lastpage": "2686",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Long-term follow-up of HIV-1-infected adults who received the F4/AS01B HIV-1 vaccine candidate in two randomised controlled trials"
    }
}